[
  {
    "ts": null,
    "headline": "Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug",
    "summary": "Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug.",
    "url": "https://finnhub.io/api/news?id=1da0af510958d5ef2d73ab4d9f5623bf281c76204c864519783192ffc5c75877",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741723605,
      "headline": "Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug",
      "id": 133185269,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug.",
      "url": "https://finnhub.io/api/news?id=1da0af510958d5ef2d73ab4d9f5623bf281c76204c864519783192ffc5c75877"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Announces Promising Phase 3 Results For Breast Cancer Therapy Vepdegestrant",
    "summary": "Pfizer (NYSE:PFE) announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in treating advanced breast cancer, which could be a significant driver of the company's modest 4% price increase over the last quarter. This development, combined with the FDA's Fast Track designation for vepdegestrant, positions the company well within the healthcare sector. Additionally, Pfizer's collaboration with Arvinas highlights its commitment to innovation, while...",
    "url": "https://finnhub.io/api/news?id=8ce3bc01dc71a701210e524a3b5f4de57b6bd180c8e4188e8e7efe3fa8990696",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741714780,
      "headline": "Pfizer (NYSE:PFE) Announces Promising Phase 3 Results For Breast Cancer Therapy Vepdegestrant",
      "id": 133185270,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in treating advanced breast cancer, which could be a significant driver of the company's modest 4% price increase over the last quarter. This development, combined with the FDA's Fast Track designation for vepdegestrant, positions the company well within the healthcare sector. Additionally, Pfizer's collaboration with Arvinas highlights its commitment to innovation, while...",
      "url": "https://finnhub.io/api/news?id=8ce3bc01dc71a701210e524a3b5f4de57b6bd180c8e4188e8e7efe3fa8990696"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=557e19d866d9df04d528f074aa9b1dcf9a2e877b2a7cd7ebc2b25e28427e4233",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741710960,
      "headline": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
      "id": 133152201,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=557e19d866d9df04d528f074aa9b1dcf9a2e877b2a7cd7ebc2b25e28427e4233"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients",
    "summary": "Pfizer and Arvinas’s therapy was able to extend progression-free-survival in just one treatment population.",
    "url": "https://finnhub.io/api/news?id=242bf4e8c55f41577a5432dae86990de9659dc4069a9a8d3f69adaaa1982a166",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741707807,
      "headline": "Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients",
      "id": 133185271,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer and Arvinas’s therapy was able to extend progression-free-survival in just one treatment population.",
      "url": "https://finnhub.io/api/news?id=242bf4e8c55f41577a5432dae86990de9659dc4069a9a8d3f69adaaa1982a166"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer : Governance Committee",
    "summary": "Charter Governance Committee Status The Governance Committee is a committee of the Board of Directors of Pfizer Inc. . ...",
    "url": "https://finnhub.io/api/news?id=2c961ecce499836f13c5dc4c199a1ed1bb563505099623751e60eac68a7cb28b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741702870,
      "headline": "Pfizer : Governance Committee",
      "id": 133136374,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Charter Governance Committee Status The Governance Committee is a committee of the Board of Directors of Pfizer Inc. . ...",
      "url": "https://finnhub.io/api/news?id=2c961ecce499836f13c5dc4c199a1ed1bb563505099623751e60eac68a7cb28b"
    }
  },
  {
    "ts": null,
    "headline": "BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund",
    "summary": "BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=0a90bbc72c21544b52437a24252fdcd27158f61d0b5128e17ea6b2ed0058f641",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741698125,
      "headline": "BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund",
      "id": 133136036,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148098716/image_2148098716.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=0a90bbc72c21544b52437a24252fdcd27158f61d0b5128e17ea6b2ed0058f641"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas gets positive breast cancer data, but finds differentiation a hard sell",
    "summary": "Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a subgroup of breast cancer patients, but not the overall study population.",
    "url": "https://finnhub.io/api/news?id=28623f682699dba7b6128524cb6be98960e632bf96ed0d43e992da58a6d4036b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741693500,
      "headline": "Arvinas gets positive breast cancer data, but finds differentiation a hard sell",
      "id": 133185272,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a subgroup of breast cancer patients, but not the overall study population.",
      "url": "https://finnhub.io/api/news?id=28623f682699dba7b6128524cb6be98960e632bf96ed0d43e992da58a6d4036b"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial",
    "summary": "– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival – – Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefit in a Phase 3 trial – NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial",
    "url": "https://finnhub.io/api/news?id=8b789ef9093b4d6b3e467c071ab757c1992be2310453c7b9a8e95c3d576de815",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741689900,
      "headline": "Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial",
      "id": 133185273,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival – – Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefit in a Phase 3 trial – NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial",
      "url": "https://finnhub.io/api/news?id=8b789ef9093b4d6b3e467c071ab757c1992be2310453c7b9a8e95c3d576de815"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Undervalued Safe Haven In Risk-Off Market​",
    "summary": "Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth potential in volatile markets. Read more here.",
    "url": "https://finnhub.io/api/news?id=8b61070ad910e5d13cac31e6ff16b01d389fd4410cc040a33a36998688e31a9f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741685400,
      "headline": "Pfizer: Undervalued Safe Haven In Risk-Off Market​",
      "id": 133133711,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689040811/image_1689040811.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth potential in volatile markets. Read more here.",
      "url": "https://finnhub.io/api/news?id=8b61070ad910e5d13cac31e6ff16b01d389fd4410cc040a33a36998688e31a9f"
    }
  },
  {
    "ts": null,
    "headline": "Q4 2024 Biontech SE Earnings Call",
    "summary": "Q4 2024 Biontech SE Earnings Call",
    "url": "https://finnhub.io/api/news?id=9d49aab1ef4a2f678ce8be340e1818cdf87a503fb8c712b0cb7ded5df9fb1e7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741669337,
      "headline": "Q4 2024 Biontech SE Earnings Call",
      "id": 133185274,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Q4 2024 Biontech SE Earnings Call",
      "url": "https://finnhub.io/api/news?id=9d49aab1ef4a2f678ce8be340e1818cdf87a503fb8c712b0cb7ded5df9fb1e7a"
    }
  }
]